Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein. (10th January 2019)

• Record Type: Journal Article
• Authors: Lou, Yanmei; Guo, Zhenzhen; Zhu, Yuanfeng; Zhang, Guiyu; Wang, Ying; Qi, Xiaoxiao; Lu, Linlin; Liu, Zhongqiu; Wu, Jinjun
• Is Part Of: Journal of ethnopharmacology. Volume 228(2018)
• Page Start: 82
• Page End: 91
• Publication Date: 2019-01-10
• Subjects: P-gp P-glycoprotein -- BCRP breast cancer resistance protein -- HQ Astragali radix -- AS-IV astragaloside IV -- CS calycosin -- FMNT formononetin -- Nrf2 nuclear factor E2-related factor-2 -- HDIs herb–drug interactions -- AREs antioxidant response elements -- Keap1 Kelch-like ECH-associated protein 1 -- Rh123 Rhodamine 123 -- tBHQ tertiary butylhydroquinone -- SFN Sulforaphane; Astragali radix -- Astragaloside IV -- Calycosin -- Formononetin -- P-glycoprotein and breast cancer resistance protein -- Nuclear factor E2-related factor-2; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2018.09.026
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Astragali radix (Huang Qi, HQ), a well-known Chinese herbal medicine, is widely coadministered with many other drugs for treating diseases. The potential herb–drug interactions (HDIs) possibly occur during the combination therapy. P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are the crucial targets that mediate the production of HDIs. We previously observed that HQ and its three main bioactive compounds, including Astragaloside IV (AS-IV), calycosin (CS) and formononetin (FMNT), could significantly induce the expression of P-gp and BCRP in HepG2 cells in vitro . However, their modulations on the function of P-gp and BCRP remain unknown; their impact on these two proteins expression in vivo is not clear; the exact regulatory mechanism has also not yet been explored. Aim of the study: This study aimed to investigate the impact of HQ, AS-IV, CS and FMNT on P-gp and BCRP in vivo, and the exact regulatory mechanism involved. The effects of HQ and these compounds on the function of P-gp and BCRP were also studied. Materials and methods: Wild-type C57BL/6 mice and nuclear factor E2-related factor-2 knockout (Nrf2 −/− ) C57BL/6 mice were orally treated with HQ, AS-IV, CS or FMNT. The protein levels of P-gp and BCRP in the liver of mice were measured by using Western blot and immunohistochemistry. The mRNA levels were measured by using real-time PCR. The activation of the drugs on the antioxidant response element (ARE)–luciferin activity was studied by using reporter assay in a stably transfected HepG2-C8 cells. The efflux activity of P-gp and BCRP in HepG2 cells were tested by using flow cytometer with typical probes. Results: HQ, AS-IV, CS and FMNT significantly upregulated the P-gp and BCRP expression in the liver of wild-type mice. The induction was significantly reversed in the Nrf2 −/− mice. HQ and these compounds significantly increased the Nrf2 expression in wild-type mice. HQ and these compounds also markedly enhanced the ARE-luciferin activity and promoted the nuclear translocation of Nrf2 in cells. Besides, HQ and these compounds significantly enhanced the efflux activity of P-gp and BCRP, and increased the intracellular ATP levels. Conclusions: Our results proved that HQ and its main bioactive compounds could induce the P-gp and BCRP expression through the activation of the Nrf2-mediated signaling pathway. HQ and these compounds also significantly enhanced the efflux activity of P-gp and BCRP, and the increased intracellular ATP levels were likely involved in the increased P-gp and BCRP function. These results suggested that potentially HDIs likely occurred when HQ was used concomitantly with other drugs that are substrates of P-gp and BCRP. Graphical abstract: